UNIVERSITÉ PARIS DESCARTES has a total of 11 patent applications. Its first patent ever was published in 2007. It filed its patents most often in EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and medical technology are CATHOLIC UNIV KOREA INDUSTRY ACADEMIC COOPERATION FOUNDATION, RENJI HOSPITAL SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE and CATHOLIC UNIV IND ACAD COOP.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 11 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Medical technology | |
#4 | Measurement | |
#5 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Measuring microorganism processes | |
#4 | Analysing materials | |
#5 | Microorganisms | |
#6 | Peptides | |
#7 | Special acyclic compounds | |
#8 | Object sterilising | |
#9 | Diagnosis and surgery | |
#10 | Implantable devices |
# | Name | Total Patents |
---|---|---|
#1 | Gogly Bruno | 3 |
#2 | Coulomb Bernard | 3 |
#3 | Lafont Antoine | 3 |
#4 | Deprez Eric | 1 |
#5 | Djerbi-Bouillie Rym | 1 |
#6 | Brossard Denis | 1 |
#7 | Dessy Chantal | 1 |
#8 | Decasper Anthony James | 1 |
#9 | Blanchet Benoît | 1 |
#10 | Slama-Schwok Anny | 1 |
Publication | Filing date | Title |
---|---|---|
EP2666869A1 | Method for determining the risk of toxicity of sorafenib in cancer patients | |
EP2480568A1 | Polypeptides and nucleic acids for treating erbb2-dependent cancers | |
EP2049164A2 | Method for treating skin wounds |